Harith Ahamed's questions to Dr Reddy's Laboratories Ltd (RDY) leadership • Q1 2026
Question
Harith Ahamed of Avendus Spark inquired about the status of the generic liraglutide filing and the potential for patent-related hurdles for the semaglutide launch in Canada.
Answer
CEO Erez Israeli confirmed that liraglutide is in the pipeline and planned for launch in the coming quarters, noting they aim to be among the first to market for the Saxenda version. Regarding semaglutide in Canada, he clarified that there is no product patent; the key hurdles are the expiration of data exclusivity in January 2026 and securing regulatory approval. He did not foresee an IP situation in Canada that would prevent their launch.